Table 3.
Treatment coverage of IVM and ALB during the first round of 2016 mass drug administration by local government area
| Akoko Edo | Ovia Northeast | Ovia Southwest | Owan East | Owan West | |
|---|---|---|---|---|---|
| Number interviewed | 1,093 | 895 | 848 | 1,016 | 1,090 |
| Reported IVM coverage (over treatment target) | 80% | 74% | 82% | 92% | 90% |
| Reported IVM coverage (over total population) | 64% | 60% | 66% | 73% | 73% |
| IVM coverage, weighted (95% CI) | 53.9% (43.3–64.2%) | 23.3% (10.4–44.2%) | 16.4% (8.2–30.0%) | 38.5% (28.3–49.8%) | 42.8% (32.3–54.0%) |
| IVM coverage, weighted, treated EAs only (95% CI) | 56.8% (46.6–67.1% | 46.3% (23.1–69.5%) | 33.9% (17.5–50.3%) | 40.1% (29.0–51.3%) | 45.7% (34.9–56.5%) |
| ALB coverage, weighted (95% CI) | 54.23% (43.8–64.7%) | – | 15.4% (7.4–29.3%) | 33.4% (24.3–43.9%) | – |
| Geographic coverage (any treatment) | 93% | 55% | 58% | 90% | 87% |
ALB = albendazole; CI = confidence intervals; EA = enumeration area; IVM = ivermectin. Ovia northeast and Owan west are not endemic for LF. The target coverage is 80% of the population.